Stock Market Reviews

PCVX (Vaxcyte, Inc.) News

Get the latest news, insights, and market updates on PCVX (Vaxcyte, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
  PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.
  Nov 20, 2025 - $PCVX
• These 3 Stocks Are Using Buybacks to Signal Market Confidence
  Buybacks are getting a boost at three $20B to $200B firms. Does Trade Desk's repurchase authorization signal confidence, or is it too early to tell?
  Nov 18, 2025 - $PCVX
• Medicxi Announces €500 Million Fund V
  Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.
  Nov 14, 2025 - $PCVX
• TD Cowen Reiterates “Buy” Rating on Vaxcyte (PCVX) With $50 PT
  With significant upside potential and hedge fund interest, Vaxcyte, Inc. (NASDAQ:PCVX) secured a spot on our list of the 15 stocks set to explode in 2026. On November 5, 2025, TD Cowen analyst Tara Bancroft reiterated her “Buy” rating on Vaxcyte, Inc. (NASDAQ:PCVX) with a $50 price target. The analyst cited positive Phase II data […]
  Nov 11, 2025 - $PCVX
• Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
  Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 Study Modified VAX-31 Infant Phase 2 Dose-Finding Study Advanced to Third and Final Stage Company Expects to Initiate VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with Topline Data in 2026 Company Establishing Fill-Finish Manufacturing in North Carolina as Key Elemen
  Nov 4, 2025 - $PCVX
• Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)
  Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks with high potential. In a report released on October 3, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) and set a price target of $134.00. In other news, Vaxcyte, Inc. (NASDAQ:PCVX) reported on September 30 that it entered […]
  Oct 8, 2025 - $PCVX
• Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal
  Thermo Fisher Scientific (TMO) shares are in focus after the company announced a multi-year manufacturing agreement with Vaxcyte that could be worth up to $1 billion. This deal further expands Thermo Fisher’s role in vaccine supply for the United States. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s multi-year manufacturing deal with Vaxcyte appears to have reignited enthusiasm among investors, driving an 11% share price gain over the past week and building...
  Oct 8, 2025 - $PCVX
• Can Thermo Fisher (TMO) Balance Biomanufacturing Expansion and AI Ambitions to Shape Its Long-Term Edge?
  Vaxcyte announced a new agreement with Thermo Fisher Scientific to provide up to US$1 billion in long-term commercial fill-finish capacity for pneumococcal conjugate vaccines at Thermo Fisher's Greenville, North Carolina facility. Thermo Fisher also entered partnerships with BenchSci to develop AI-powered research tools and with AstraZeneca’s BioVentureHub for collaborative R&D in chromatography, genomics, and proteomics. These collaborations highlight Thermo Fisher's dual focus on expanding...
  Oct 2, 2025 - $PCVX
• Thermo Fisher (TMO) Stock Trades Up, Here Is Why
  Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 9% in the afternoon session after the company secured a major manufacturing agreement with biotechnology firm Vaxcyte and announced a new AI-focused partnership.
  Oct 1, 2025 - $PCVX
• What Does Wall Street Think About Vaxcyte (PCVX)?
  Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best strong buy stocks to invest in according to Wall Street. Goldman Sachs initiated coverage of Vaxcyte, Inc. (NASDAQ:PCVX) on September 12 with a Neutral rating and a $38 price target. However, Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) on August 16, […]
  Sep 30, 2025 - $PCVX